A bone disorder with low bone density, impaired bone architecture and low bone strength leading to predisposed fractures is termed as Osteoporosis [1]. Since the bone loss occurs without symptoms this is often called as the silent disease [2]. Due to reduced bone formation loss of bone mass occurs in either third or fourth decade in both men and women [1].

References

1. Barbara G Wells., et al. “Pharmacotherapy Handbook”. Ninth edition. McGraw-Hill Education (2014).
2. NIH National Osteoporosis and Related Bone diseases National Resource Centre. Osteoporosis Overview. National Institute of Arthritis and Musculoskeletal and Skin Diseases (2018).
3. Joann L. Porter and Matthew Varacallo. StatPearls. NCBI Bookshelf (2020).
4. Highlights of prescribing information. U S Food Drug Administration (2019).
5. F Cosman., et al. “Romosozumab treatment in post menopausal women with osteoporosis”. The New England Journal of Medicine16 (2016): 1522-1543.
6. Anne Sophie Koldkjaer Solling., et al. “The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with Osteoporosis”. Therapeutic Advances in Musculoskeletal Disease5-6 (2018): 105-115.
7. Akimistu Miyauchi., et al. “Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension”. Archives of Osteoporosis 1 (2019): 59.
8. Kenneth G Sag., et al. “Romosozumab or Alendronate for fracture prevention in women with osteoporosis”. The New England Journal of Medicine 15 (2017): 1471-1427.

Citation

Citation: Sirigiri Kusuma. “An Editorial: Osteoporosis and Romosozumab".Acta Scientific Pharmacology 1.8 (2020): 01-02.

Copyright

Copyright: © 2020 Sirigiri Kusuma. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.